In this episode, Simon Allard from Amneal Pharmaceuticals joins the YOPN podcast team to share his journey from neuroscience research to his role as a medical science liaison—and to give listeners a rare, behind-the-scenes look at how Parkinson’s drugs are developed, tested, and refined in real life.

Simon unpacks the science behind preclinical research, the phases of clinical trials, and the differences between extended-release Levodopa formulations. He also explains how real-world feedback from patients and clinicians continues to shape dosing, safety, and access.

Together with the hosts, Simon explores gaps in trial representation, the promise of wearable technology, and why open communication between clinicians, patients, and pharma matters. The episode highlights the vital role of patient advocacy, participation in research, and how the combination of effective symptom management and regular exercise can help people with YOPD live well today—while science pushes toward tomorrow’s disease-modifying therapies.